SIFI > Disclosure of Transfers of Value
Disclosure of Transfers of value 
SIFI is a pharmaceutical company committed to fulfilling the needs of its customers, both patients and ophthalmologists.
SIFI strongly believes that only a stable and constructive cooperation between healthcare professionals and the company can provide real benefits to patients.
SIFI is compliant with the Disclosure Code by Farmindustria (Italy), given that the implementation of the EFPIA Code (EFPIA: European Federation of Pharmaceutical Industries) aims at the standardization in Europe of the behavior of companies and their relations with healthcare professionals.
“Disclosure” is the keyword for companies associated with Farmindustria, intended in order to disclose all transfers of value, both direct and indirect, between the pharmaceutical companies and healthcare professionals and organizations
The commitment to Disclosure is fulfilled by publishing transfers of value from the pharmaceutical company to the healthcare professionals and organizations on the company website, in the following fields of activity:
1. research and development of new drugs by clinical trials carried out at hospitals, universities and public and private health structures;
2. scientific consultancies;
3. symposia and scientific meetings providing educational and updated contents;
4. sponsorship of CME (Continuing Medical Education) meetings and courses, organized by public structures, universities, scientific societies and accredited CME providers.
These relationships are disciplined by national and international laws and are based on the mutual respect of the roles in a context of disclosure established by Farmindustria Ethical Conduct which provide for rigorous inspections carried out during precise investigation procedures by third party entities, chaired by magistrates appointed by the President of the Italian “Corte di Cassazione”
Data concerning Transfers of Value will be published only if the doctor agrees to publication by signing the specific form.
Data collected by companies will be treated and processed according to current policies and regulations.
If consent to publication is not available, the company is however bound to publish the data in a comprehensive form.
Data concerning relations of cooperation between SIFI Group and Health Care Professionals (HCPs) or Health Care Organizations (HCOs), and data relating to SIFI Research and Development (R&D) will be available starting June 30th 2016 on SIFI website
S.I.F.I. S.p.A. – Disclosure of Transfers of value: data January 1st – December 31st, 2015
EYELAB S.r.l. – Disclosure of Transfers of value: data January 1st – June 30th, 2015
Oftafarma S.r.l. - Disclosure of Transfers of value: data January 1st – December 31st, 2015

S.I.F.I. S.p.A. – Disclosure of Transfers of value: data January 1st – December 31st, 2016
Oftafarma S.r.l. - Disclosure of Transfers of value: data January 1st – December 31st, 2016

Method of data processing
The single item of transfers of values, expressed in euros, was processed according to the criteria of relevance and accrual basis and reported before VAT in all cases in which the tax is deductible for the company.
“Vision is the art of seeing what is invisible to others.”
Jonathan Swift

Vision & History Established in 1935 by two local pharmacists in Sicily, SIFI started as a venture, specializing in the preparation of ophthalmic products. Since then, research, development,...
SIFI Group has a Vigilance system that allows us to take full responsibility for our medical and non medical products, both marketed or in clinical development and to take appropriate...
General questions   Products Quality       Pharmacovigilance   Vigilance...

On our Social Channels

From our News Center

SIFI to strengthen R&D Pipeline with Pro-Ocular™ containing a neurosteroid with novel dosage delivery system that activates neural signaling to produce endogenous tear film without...


08 June

Don't miss the SIFI Symposium at the XIX G.I.Vre Italian Group of Vitreoretinal Surgery on treatment of diabetic macular edema presenting three-year data of the "real...
Follow Us!